Equities Analysts Offer Predictions for ALUR Q1 Earnings

Allurion Technologies Inc. (NYSE:ALUR) – Equities research analysts at Roth Capital reduced their Q1 2025 earnings estimates for Allurion Technologies in a research note issued on Wednesday, March 5th. Roth Capital analyst J. Wittes now expects that the company will earn ($22.91) per share for the quarter, down from their previous estimate of ($3.25). The consensus estimate for Allurion Technologies’ current full-year earnings is ($9.96) per share. Roth Capital also issued estimates for Allurion Technologies’ Q2 2025 earnings at ($17.35) EPS, Q3 2025 earnings at ($14.19) EPS, Q4 2025 earnings at ($3.61) EPS, FY2025 earnings at ($58.06) EPS and FY2026 earnings at ($4.41) EPS.

Separately, Chardan Capital downgraded shares of Allurion Technologies from a “buy” rating to a “neutral” rating in a research note on Thursday, November 14th.

Allurion Technologies Stock Performance

Shares of ALUR opened at $2.33 on Monday. The company has a market capitalization of $11.15 million, a price-to-earnings ratio of -0.19 and a beta of -0.59. The company’s 50 day simple moving average is $4.88 and its 200 day simple moving average is $10.87. Allurion Technologies has a 1 year low of $2.15 and a 1 year high of $98.75.

Hedge Funds Weigh In On Allurion Technologies

An institutional investor recently raised its position in Allurion Technologies stock. Geode Capital Management LLC raised its stake in Allurion Technologies Inc. (NYSE:ALUR) by 40.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 516,330 shares of the company’s stock after purchasing an additional 149,484 shares during the quarter. Geode Capital Management LLC owned about 0.80% of Allurion Technologies worth $317,000 at the end of the most recent quarter. 21.39% of the stock is currently owned by institutional investors and hedge funds.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.